The Effect of Diabetes Mellitus, Insulin, and Thiazolidinediones on Bone Histomorphometry in Streptozotocin-induced Diabetic Postmenopausal Wistar Rats

Gülnur  Take Kaplanoğlu; Derya  Köseoğlu; Banu  Aktaş Yılmaz3; Erdal  Kan; Nuri  Çakır

doi:10.52981/sjms.v16i1.1097

Gülnur Take Kaplanoğlu Gazi University, Yenimahalle/Ankara
Derya Köseoğlu Hitit University
Banu Aktaş Yılmaz3 Ufuk University, Gölbaşı/Ankara,
Erdal Kan Medicana Samsun Hospital
Nuri Çakır Faculty of Medicine, Gazi University

DOI: https://doi.org/10.52981/sjms.v16i1.1097

Keywords: diabetes mellitus, bone, osteoporosis, bone histomorphometry, rosiglitazone, insulin, thiazolidinediones

Abstract

Background: Osteoporosis is a metabolic skeletal disease with low bone mass and bone microarchitectural disorganization. Thiazolidinediones (TZD) increase insulin sensitivity through activation of peroxisome proliferator-activated receptor gamma (PPARγ). One of the most important side effects of this drugs is its effects on bone, especially in postmenopausal women. The purpose of this study was to evaluate the effect of diabetes mellitus (DM), insulin, and TZDs on bone in postmenopausal Wistar rats.

Methods: Sixteen postmenopausal Wistar rats were divided into four groups: (i) control group, (ii) Streptozotocin-induced DM group without treatment, (iii) Streptozotocininduced DM group with insulin therapy, and (iv) Streptozotocin-induced DM group receiving rosiglitazone. Pictures of the obtained samples were taken under computerequipped photo-light microscope, and bone tissue ratios were calculated in an area of 1 mm2. In this area, trabecular thicknesses were measured from six randomly selected regions. In addition, femoral neck regions were determined by measuring the farthest distance.

Results: Compared to the control group, trabecular thicknesses were decreased in the uncontrolled DM and rosiglitazone groups. In the rosiglitazone-treated group, trabecular thickness was decreased compared to the uncontrolled DM group. The histological examination of the bones showed that uncontrolled DM and rosiglitazone treatment negatively affected the osteoblast and osteocyte activity. Insulin-treated group had a similar histologic examination compared to the control group.

Conclusion: Our study showed that DM had unfavorable effects on bones, and rosiglitazone further exerts this effect. However, the negative effect of DM may be neutralized with the use of insulin.

References

[1] Vestergaard, P. (2007). Discrepancies in bone mineral density and fracture risk inpatients with type 1 and type 2 diabetes–a meta-analysis. Osteoporosis International,vol. 18, no. 4, pp. 427–444.
[2] Miao, J., Brismar, K., Nyrén, O., et al. (2005). Elevated hip fracture risk in type 1 diabeticpatients: a population-based cohort study in Sweden. Diabetes Care, vol.28, no.12,pp. 2850–2855.
[3] Grey, A. (2009). Thiazolidinedione-induced skeletal fragility–mechanisms andimplications. Diabetes, Obesity & Metabolism, vol. 11, no. 4, pp. 275–284.
[4] Ahmed, L. A., Joakimsen, R. M., Berntsen, G. K., et al. (2006). Diabetes mellitus andthe risk of non-vertebral fractures: the Tromsø study. Osteoporosis International, vol.17, no. 4, pp. 495–500.
[5] Janghorbani, M., Van Dam, R. M., Willett, W. C., et al. (2007). Systematic reviewof type 1 and type 2 diabetes mellitus and risk of fracture. American Journal ofEpidemiology, vol. 166, no. 5, pp. 495–505.
[6] Nicodemus, K. K., Folsom, A. R., and Iowa Women’s Health Study. (2001). Type 1and type 2 diabetes and incident hip fractures in postmenopausal women. DiabetesCare, vol. 24, no. 7, pp. 1192–1197.
[7] Gimble, J. M., Robinson, C. E., Wu, X., et al. (1996). Peroxisome proliferator-activatedreceptor-gamma activation by thiazolidinediones induces adipogenesis in bonemarrow stromal cells. Molecular Pharmacology, vol. 50, no. 5, pp. 1087–1094.
[8] Grey, A. (2008). Skeletal consequences of thiazolidinedione therapy. OsteoporosisInternational, vol. 19, no. 2, pp. 129–137.
[9] Kawaguchi, H., Akune, T., Yamaguchi, M., et al. (2005). Distinct effects of PPARgammainsufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. Journal ofBone and Mineral Metabolism, vol. 23, no. 4, pp. 275–279.[10] Mbalaviele, G., Abu-Amer, Y., Meng, A., et al. (2000). Activation of peroxisomeproliferator-activated receptor-gamma pathway inhibits osteoclast differentiation.The Journal of Biological Chemistry, vol. 275, no. 19, pp. 14388–14393.
[11] Okazaki, R., Toriumi, M., Fukumoto, S., et al. (1999). Thiazolidinediones inhibitosteoclast-like cell formation and bone resorption in vitro. Endocrinology, vol. 140,no. 11, pp. 5060–5065.
[12] Ali, A. A., Weinstein, R. S., Stewart, S. A., et al. (2005). Rosiglitazone causes bone lossin mice by suppressing osteoblast differentiation and bone formation. Endocrinology,vol. 146, no. 3, pp. 1226–1235.
[13] Lazarenko, O. P., Rzonca, S. O., Hogue, W. R., et al. (2007). Rosiglitazoneinduces decreases in bone mass and strength that are reminiscent of agedbone. Endocrinology, vol. 148, no. 6, pp. 2669–2680.
[14] Kanda, J., Izumo, N., Kobayashi, Y., et al. (2017). Effect of the antidiabetic agentpioglitazone on bone metabolism in rats. Journal of Pharmacological Sciences, vol.135, no. 1, pp. 22–28.
[15] Sottile, V., Seuwen, K., and Kneissel, M. (2004). Enhanced marrow adipogenesisand bone resorption in estrogen-deprived rats treated with the PPARgamma agonistBRL49653 (rosiglitazone). Calcified Tissue International, vol. 75, no. 4, pp. 329–337.
[16] Zhang, L., Liu, Y., Wang, D., et al. (2009). Bone biomechanical and histomorphometricalinvestment in type 2 diabetic Goto-Kakizaki rats. Acta Diabetologica, vol. 46,no. 2, pp. 119–126.
[17] Schwartz, A. V. (2003). Diabetes mellitus: does it affect bone? Calcified TissueInternational, vol. 73, no. 6, pp. 515–519.
[18] Epstein, S. and LeRoith, D. (2008). Diabetes and fragility fractures – a burgeoningepidemic? Bone, vol. 43, no. 1, pp. 3–6.
[19] Hamada, Y., Kitazawa, S., Kitazawa, R., et al. (2007). Histomorphometric analysisof diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role ofoxidative stress. Bone, vol. 40, no. 5, pp. 1408–1414.
[20] Ying, X., Chen, X., Wang, T., et al. (2020). Possible osteoprotective effects of myricetinin STZ induced diabetic osteoporosis in rats. European Journal of Pharmacology,vol. 866, p. 172805.
[21] Merlotti, D., Gennari, L., Dotta, F., et al. (2010). Mechanisms of impaired bone strengthin type 1 and 2 diabetes. Nutrition, Metabolism, and Cardiovascular Diseases, vol. 20,no. 9, pp. 683–690.
[22] Valcourt, U., Merle, B., Gineyts, E., et al. (2007). Non-enzymatic glycation of bonecollagen modifies osteoclastic activity and differentiation. The Journal of BiologicalChemistry, vol. 282, no. 8, pp. 5691–5703.
[23] Lecka-Czernik, B., Gubrij, I., Moerman, E. J., et al. (1999). Inhibition of Osf2/Cbfa1expression and terminal osteoblast differentiation by PPARgamma2. Journal ofCellular Biochemistry, vol. 74, no. 3, pp. 357–371.
[24] Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., et al. (2006). Thiazolidinedione useand bone loss in older diabetic adults. The Journal of Clinical Endocrinology andMetabolism, vol. 91, no. 9, pp. 3349–3354.
[25] Eom, Y. S., Gwon, A. R., Kwak, K. M., et al. (2016). Protective effects of vildagliptinagainst pioglitazone-induced bone loss in type 2 diabetic rats. PloS ONE, vol. 11, no.12, p. e0168569.
[26] Rzonca, S. O., Suva, L. J., Gaddy, D., et al. (2004). Bone is a target for the antidiabeticcompound rosiglitazone. Endocrinology, vol. 145, no. 1, pp. 401–406.
[27] Hofbauer, L. C., Brueck, C. C., Singh, S. K., et al. (2007). Osteoporosis in patientswith diabetes mellitus. Journal of Bone and Mineral Research, vol. 22, no. 9, pp.1317–1328.
[28] Valerio, G., del Puente, A., Esposito-del Puente, A., et al. (2002). The lumbar bonemineral density is affected by long-term poor metabolic control in adolescents withtype 1 diabetes mellitus. Hormone Research, vol. 58, no. 6, pp. 266–272.
[29] Kumar, S., Hoffman, S. J., Samadfam, R., et al. (2013). The effect of rosiglitazone onbone mass and fragility is reversible and can be attenuated with alendronate. Journalof Bone and Mineral Research, vol. 28, no. 7, pp. 1653–1665.